MES

Prothrombin Time Comes in Small (CLIA-Waived) Packages

Determining prothombin levels is necessary to plan or evaluate anticoagulant therapy, to diagnose various inherited conditions, such as hyperhomocystinemia, elevated factor VIII levels, dysfibrinogenemia, factor XII deficiency and disorders of plasmin generation, and to assess acquired conditions, such as pregnancy, postoperative state, antiphospholipid syndrome, hyperhomocystinemia, among ot...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29

Company to Proceed with Development Program for Oral Compoundsto Treat Alcohol Dependence CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc.(Nasdaq: ALKS) today announced positive preliminary results from aclinical trial of ALKS 29 in alcohol dependent patients. Based onthese results, the company plans to move forward with itsdevelopment program for oral product...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated(Nasdaq:INSM), a biopharmaceutical company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet medical needs, today noted the publication ofpromising results of research from three universities regarding thepotential role of insulin-like growth factor binding protein-3(IGFBP-3) in...

Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates

'Superbug' Prevalence Data from 1,237 Facilities DemonstratesPublic Health Threat; Colonization and Infections Span All States,Across Healthcare Facility Units SAN JOSE, Calif., June 25, 2007 /PRNewswire-USNewswire/ -- TheAssociation for Professionals in Infection Control and Epidemiology(APIC) today released initial results from a nationwide study of1,237 U.S. healthcare facilities, exam...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase IIIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex -the novel selective relaxant binding agent (SRBA) being developedby Organon, the human healthcare business unit of Akzo Nobel -demonstrated in a Phase III pivotal trial a 9-12 times fasterreversal of neuromuscular blockade as compared to neostigmine,without evidence of post operative residual curarization (PORC) orre-occurre...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novelselective relaxant binding agent (SRBA) being developed by Organon,the human healthcare business unit of Akzo Nobel - demonstrated ina Phase III pivotal trial a 9-12 times faster reversal ofneuromuscular blockade as compared to neostigmine, without evidenceof post operative residual curarization (PORC) or re-occurrence ofmuscle relax...

Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's AAGP

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 7, 2007 - As afollow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 pressrelease related to cryopreserved (or frozen) cells treated withAAGP(TM), in collaboration with the University of Helsinki,Finland, ProtoKinetix has recently finished a set of trialsdesigned to determine whether AAGP(TM) treated cells could surviveafter preservation...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigatorsreported today that Soliris(TM) (eculizumab), a new treatment forparoxysmal nocturnal hemoglobinuria (PNH) developed by AlexionPharmaceuticals, Inc. , is effective in patients diagnosed with PNHwho have a history of aplastic anemia (AA) or myelodysplasticsyndromes (MDS). Soliris...

Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)

First Release of Data for New Combination PARSIPPANY, NJ(May 21, 2007) -- Combining the calcium channel blockeramlodipine besylat...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients takingonce-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- Along-term phase III, open-label 12-14 month extension study (303)presented at the British Society of Gastroenterology (BSG) meetingin Glasgow, Scotland in March 2007 showed Shire plc'sLialda(mesalamine) is w...

Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)

First Release of Data for New Combination PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- Combining thecalcium channel blocker amlodipine besylate with the angiotensinreceptor blocker olmesartan medoxomil, produced significant meanreductions in seated systolic and diastolic blood pressure inpatients with hypertension, according to data presented at theAmerican Society of Hypertension's Twe...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells

Clinical Data Presented at the Society for InvestigativeDermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGIDermatics today announced new clinical research that the8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomesenhances DNA repair and reduces MMP-1 and TNF-alpha in UVirradiated skin cells. The data was presented at the 68th AnnualMeeting of the Society fo...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a globalspecialty pharmaceutical and medical device company, announced thatthe two-year data from its European pivotal trial examining theVascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)")will be presented today at a scientific forum in Europe. Thetwo-year study examine...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

Data supporting three Antisoma programmes presented at AACR

LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces thatpreclinical data supporting three of its drugs are presented thisweek at the Annual Meeting of the American Association of CancerResearch (AACR). AS1404-Avastin-paclitaxel triple combination highly effectiveAntisoma's scientists have for the first time evaluated a triplecombination of the Company's vascular disrupting a...

Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds

STANFORD, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - The two mostprevalent forms of genetic mental retardation, Fragile X and Downsyndromes, may share a common cause, according to researchers atStanford University School of Medicine. The problem, a crippledcommunication network in the brain, may also be associated withautism. Although the genetics of the disorders are very different, theend...